Serum Alkaline Phosphate Level Associates with Metabolic Syndrome Components Regardless of Non-Alcoholic Fatty Liver; A Population-Based Study in Northern Iran

Abstract

Background:

Serum alkaline phosphatase (ALP) is an indicator of hepatobiliary disorders, such as  metabolic syndrome (MetS).

To assess the association between serum ALP levels and metabolic syndrome (MetS), with or without non-alcoholic fatty liver disease (NAFLD), in a cohort study in northern Iran.

 Methods:

Data from approximately 5257 subjects aged more than 18 years participating in the Amol cohort were used. We extracted the required data and investigated the correlation between liver enzyme levels and MetS. Multiple logistic regression analyses based on the serum ALP quartiles were performed.

Results:

Of them, 2860 were male with a mean age of 42.11± 16.1 years. A positive linear trend was observed between serum ALP levels and the number of MetS components in both sexes. In both sexes, systolic blood pressure, waist circumferences, and HDL had a significant association with ALP. After adjusting for age, both sexes with NAFLD showed an increased risk of developing MetS. The risk of NAFLD increased in individuals with > 2nd quartile of ALP. Furthermore, higher ALP levels were associated with an increased risk of MetS in males (1.1014 [0.782–1.315] ) and females (1.441 [1.085–1.913]).

Conclusion:

There is a significant association between serum ALP levels and MetS, independent of fatty liver changes, suggesting that this marker can be considered as a feasible predictor of MetS.